{"id":"nepidermin","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NEPIDERMIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:08:26.635052+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:08:33.224686+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NEPIDERMIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:08:34.010470+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108314/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:34.483911+00:00"}},"allNames":["nepidermin"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Nepidermin's mechanism of action is not well understood, but it is believed to involve the interaction with specific receptors or enzymes to produce a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=nepidermin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nepidermin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:26:31.156409","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:36.361861+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"nepidermin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07137416","phase":"PHASE1","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-05","conditions":["Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Invasive Breast Carcinoma","Locally Advanced Breast Carcinoma","Metastatic Breast Carcinoma","Metastatic HER2-Low Breast Carcinoma","Metastatic HER2-Positive Breast Carcinoma","Metastatic Hormone Receptor-Positive Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Triple-Negative Breast Carcinoma","Unresectable Breast Carcinoma","Unresectable HER2-Low Breast Carcinoma","Unresectable HER2-Positive Breast Carcinoma","Unresectable Hormone Receptor-Positive Breast Carcinoma","Unresectable Malignant Solid Neoplasm","Unresectable Triple-Negative Breast Carcinoma"],"enrollment":36,"completionDate":"2028-01-10"},{"nctId":"NCT06761976","phase":"","title":"Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation","status":"AVAILABLE","sponsor":"Bayer","startDate":"","conditions":["Advanced Non-small Cell Lung Cancer","Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","HER2-Negative Breast Carcinoma","Hormone Receptor-Positive Breast Carcinoma"],"enrollment":3680,"completionDate":"2026-05-31"},{"nctId":"NCT07493291","phase":"","title":"Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-09-07","conditions":["Brest Cancer","CDK4/6 Inhibitor"],"enrollment":100,"completionDate":"2026-04-20"},{"nctId":"NCT07498478","phase":"PHASE2","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","status":"RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-03-17","conditions":["Breast Cancer"],"enrollment":94,"completionDate":"2027-12-31"},{"nctId":"NCT06635447","phase":"PHASE3","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-26","conditions":["Breast Cancer"],"enrollment":258,"completionDate":"2027-01-10"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT07498413","phase":"","title":"Epidemiology and Treatment of HR+/HER2- Breast Cancer in England","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-08","conditions":["Breast Cancer"],"enrollment":218677,"completionDate":"2025-07-18"},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":["Breast Neoplasms"],"enrollment":600,"completionDate":"2029-12"},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":["HER2-positive Breast Cancer"],"enrollment":544,"completionDate":"2029-09"},{"nctId":"NCT05963997","phase":"PHASE1,PHASE2","title":"A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-10-09","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer"],"enrollment":49,"completionDate":"2026-03-06"},{"nctId":"NCT05748834","phase":"PHASE2","title":"Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-07-24","conditions":["Breast Cancer"],"enrollment":36,"completionDate":"2027-11"},{"nctId":"NCT06827236","phase":"PHASE1,PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":["Locally Advanced Breast Cancer","Unresectable Breast Carcinoma","Metastatic Breast Cancer"],"enrollment":380,"completionDate":"2029-05"},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":["Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer","Estrogen-receptor-positive Breast Cancer","Hormone Receptor Negative Breast Carcinoma"],"enrollment":700,"completionDate":"2031-06-02"},{"nctId":"NCT06188559","phase":"PHASE2","title":"A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2024-04-10","conditions":["Breast Cancer"],"enrollment":135,"completionDate":"2027-03-31"},{"nctId":"NCT05659563","phase":"PHASE2","title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%","status":"COMPLETED","sponsor":"MedSIR","startDate":"2023-07-20","conditions":["Breast Cancer","Breast Cancer, Early-Onset"],"enrollment":92,"completionDate":"2025-01-30"},{"nctId":"NCT06590857","phase":"PHASE1,PHASE2","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","status":"ACTIVE_NOT_RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2024-07-19","conditions":["Metastatic Breast Cancer","HER2-negative Breast Cancer","ER+ Breast Cancer","Advanced Breast Cancer"],"enrollment":16,"completionDate":"2033-01"},{"nctId":"NCT05323955","phase":"PHASE2","title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carey Anders, M.D.","startDate":"2023-03-23","conditions":["Brain Metastases","Human Epidermal Growth Factor 2 Positive Carcinoma of Breast","Advanced Breast Cancer"],"enrollment":48,"completionDate":"2026-07"},{"nctId":"NCT06843967","phase":"PHASE1,PHASE2","title":"A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-19","conditions":["Well Differentiated Liposarcoma","Dedifferentiated Liposarcoma","Liposarcoma","Myxoid Liposarcoma","Round Cell Liposarcoma","Myxoid Pleomorphic Liposarcoma","Pleomorphic Liposarcoma","Unresectable Liposarcoma","Unresectable Dedifferentiated Liposarcoma"],"enrollment":54,"completionDate":"2028-08-19"},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":["HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients"],"enrollment":55,"completionDate":"2025-12-23"},{"nctId":"NCT05364073","phase":"PHASE1","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2022-06-30","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","HER2 Exon 20 Mutations","EGFR Exon 20 Mutations","EGFR Uncommon Mutations, Including G719X and S768I"],"enrollment":160,"completionDate":"2026-12-31"},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":["Breast Neoplasms","Breast Cancer"],"enrollment":372,"completionDate":"2034-12-31"},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":["Gastric Cancer"],"enrollment":226,"completionDate":"2027-07-31"},{"nctId":"NCT07070232","phase":"PHASE1,PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":["Advanced Solid Tumor"],"enrollment":980,"completionDate":"2029-10"},{"nctId":"NCT05913440","phase":"","title":"HER2-low Unresectable and/or Metastatic Breast Cancer in Russia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-05-30","conditions":["Breast Cancer"],"enrollment":1669,"completionDate":"2025-03-14"},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":["Endometrial Cancer"],"enrollment":600,"completionDate":"2031-02-19"},{"nctId":"NCT04862663","phase":"PHASE3","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-10","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"enrollment":895,"completionDate":"2029-08-14"},{"nctId":"NCT05099172","phase":"PHASE1,PHASE2","title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-10-25","conditions":["Advanced Non-small Cell Lung Cancer","EGFR Mutation","HER2 Mutation"],"enrollment":370,"completionDate":"2026-12-31"},{"nctId":"NCT07100106","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2025-10-07","conditions":["Breast Cancer"],"enrollment":285,"completionDate":"2028-08-31"},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":500,"completionDate":"2028-09-30"},{"nctId":"NCT07310420","phase":"PHASE1","title":"A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"TerSera Therapeutics LLC","startDate":"2026-04-29","conditions":["Advanced Breast Cancer"],"enrollment":88,"completionDate":"2027-03-30"},{"nctId":"NCT06902545","phase":"","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","status":"RECRUITING","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2025-04-03","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":377,"completionDate":"2030-07-31"},{"nctId":"NCT04895358","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-06-18","conditions":["Breast Neoplasms"],"enrollment":340,"completionDate":"2027-12-18"},{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":["Metastatic Triple Negative Breast Cancer"],"enrollment":273,"completionDate":"2026-09-04"},{"nctId":"NCT07413939","phase":"PHASE2,PHASE3","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","status":"NOT_YET_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-04-30","conditions":["HER2-positive Breast Cancer"],"enrollment":650,"completionDate":"2032-08-28"},{"nctId":"NCT04589845","phase":"PHASE2","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-01-18","conditions":["Solid Tumors"],"enrollment":920,"completionDate":"2032-09-25"},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":["Metastatic Breast Cancer"],"enrollment":541,"completionDate":"2028-07"},{"nctId":"NCT07214662","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2026-01-13","conditions":["Breast Cancer"],"enrollment":136,"completionDate":"2030-04-01"},{"nctId":"NCT06760819","phase":"PHASE2","title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2025-02-13","conditions":["Advanced Solid Tumors","HER2 Mutation"],"enrollment":111,"completionDate":"2027-10-25"},{"nctId":"NCT05579366","phase":"PHASE1,PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":["High Grade Epithelial Ovarian Cancer","High Grade Serous Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)","Mesothelioma","Breast Adenocarcinoma","Triple Negative Breast Cancer","Hormone Receptor-positive/Her2 Negative Breast Cancer","Platinum-resistant Ovarian Cancer (PROC)","Platinum Sensitive Ovarian Cancer (PSOC)","Primary Refractory Ovarian Cancer","Uterine Cancer"],"enrollment":764,"completionDate":"2027-10"},{"nctId":"NCT03701334","phase":"PHASE3","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-07","conditions":["Early Breast Cancer"],"enrollment":5101,"completionDate":"2030-05-29"},{"nctId":"NCT06982521","phase":"PHASE3","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2025-08-26","conditions":["PIK3CA Mutation","HER2- Negative Breast Cancer","Hormone Receptor Positive Tumor","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer"],"enrollment":540,"completionDate":"2031-12-31"},{"nctId":"NCT05325632","phase":"PHASE2","title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-10-28","conditions":["HER2-positive Breast Cancer"],"enrollment":53,"completionDate":"2027-09"},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":["Breast Cancer"],"enrollment":1020,"completionDate":"2037-12-29"},{"nctId":"NCT06452277","phase":"PHASE3","title":"A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-08-28","conditions":["Advanced Non-small Cell Lung Cancer","HER2 Mutation"],"enrollment":278,"completionDate":"2029-06-27"},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":["Early Breast Cancer"],"enrollment":1400,"completionDate":"2030-09-20"},{"nctId":"NCT05187832","phase":"PHASE1","title":"A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2022-10-05","conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":61,"completionDate":"2026-11"},{"nctId":"NCT05573893","phase":"","title":"PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-09-12","conditions":["Breast Neoplasms","Breast Cancer","Neoplasm Metastasis"],"enrollment":800,"completionDate":"2031-12-31"},{"nctId":"NCT04288089","phase":"PHASE1","title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eisai Inc.","startDate":"2020-04-01","conditions":["Receptors, Estrogen","Genes, Erbb-2","Breast Neoplasms"],"enrollment":31,"completionDate":"2027-03-31"},{"nctId":"NCT04498481","phase":"","title":"TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-01","conditions":["Breast Cancer"],"enrollment":1,"completionDate":"2018-07-01"},{"nctId":"NCT05593094","phase":"PHASE1,PHASE2","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-03","conditions":["Advanced Solid Tumors","HER2-positive Breast Cancer"],"enrollment":210,"completionDate":"2027-07-31"},{"nctId":"NCT07431281","phase":"PHASE3","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-03","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Esophageal Cancer"],"enrollment":2130,"completionDate":"2031-10-27"},{"nctId":"NCT07427394","phase":"PHASE2","title":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-04-10","conditions":["Advanced Breast Cancer"],"enrollment":24,"completionDate":"2027-12-03"},{"nctId":"NCT05113251","phase":"PHASE3","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-25","conditions":["Breast Neoplasms","Breast Cancer","HER2-positive Early Breast Cancer"],"enrollment":927,"completionDate":"2027-04-30"},{"nctId":"NCT05022342","phase":"","title":"Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-27","conditions":["Breast Cancer"],"enrollment":595,"completionDate":"2025-02-11"},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":["Breast Cancer"],"enrollment":42,"completionDate":"2028-11"},{"nctId":"NCT07416409","phase":"","title":"Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Deraya University","startDate":"2023-06-10","conditions":["Breast Neoplasms","Oncology","HER2-positive Breast Cancer","Metastatic Breast Cancer"],"enrollment":80,"completionDate":"2025-06-20"},{"nctId":"NCT07227233","phase":"PHASE2","title":"Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-04","conditions":["Breast Cancer"],"enrollment":105,"completionDate":"2028-12"},{"nctId":"NCT03587740","phase":"PHASE2","title":"ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-22","conditions":["Breast Cancer"],"enrollment":82,"completionDate":"2027-08-30"},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":["Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","HER2-positive Breast Cancer","Breast Cancer"],"enrollment":74,"completionDate":"2036-07-01"},{"nctId":"NCT06224673","phase":"PHASE2","title":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2026-03-01","conditions":["HER2 Low Breast Carcinoma","Triple Negative Breast Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma"],"enrollment":36,"completionDate":"2029-06-30"},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":["Advanced or Metastatic Breast Cancer"],"enrollment":333,"completionDate":"2028-01-21"},{"nctId":"NCT06330064","phase":"PHASE2","title":"A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-04-10","conditions":["Recurrent or Metastatic Solid Tumors"],"enrollment":520,"completionDate":"2028-07-25"},{"nctId":"NCT06824155","phase":"EARLY_PHASE1","title":"HEAT Trial (HER2 Antibody Therapy With Lutetium-177)","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2025-02-12","conditions":["HER2 Gene Mutation","Advanced Solid Tumors"],"enrollment":30,"completionDate":"2027-12"},{"nctId":"NCT04739761","phase":"PHASE3","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-22","conditions":["Breast Cancer"],"enrollment":506,"completionDate":"2026-05-26"},{"nctId":"NCT04072952","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arvinas Estrogen Receptor, Inc.","startDate":"2019-08-05","conditions":["Breast Cancer"],"enrollment":217,"completionDate":"2026-02-27"},{"nctId":"NCT02513394","phase":"PHASE3","title":"PALbociclib CoLlaborative Adjuvant Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2015-08","conditions":["Breast Cancer"],"enrollment":5796,"completionDate":"2028-12"},{"nctId":"NCT05333874","phase":"EARLY_PHASE1","title":"CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-04-06","conditions":["Breast Cancer, Early-Onset"],"enrollment":34,"completionDate":"2027-11-28"},{"nctId":"NCT06250777","phase":"PHASE2","title":"Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases","status":"ENROLLING_BY_INVITATION","sponsor":"Yonsei University","startDate":"2024-07-11","conditions":["Non Small Cell Lung Cancer"],"enrollment":27,"completionDate":"2026-12"},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":["Metastatic Breast Cancer"],"enrollment":331,"completionDate":"2026-12"},{"nctId":"NCT05115474","phase":"","title":"Study of Screening Brain MRIs in Stage IV Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-12-21","conditions":["Triple Negative Breast Cancer","HER2-positive Breast Cancer","Hormone Receptor-positive Breast Cancer"],"enrollment":170,"completionDate":"2026-10"},{"nctId":"NCT05694364","phase":"PHASE1","title":"Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-01-25","conditions":["Chronic Lymphocytic Leukemia","Mantle Cell Lymphoma","Acute Lymphoblastic Leukemia","Diffuse Large B Cell Lymphoma","Triple Negative Breast Cancer Malignancies"],"enrollment":3,"completionDate":"2024-04-18"},{"nctId":"NCT04273555","phase":"PHASE1,PHASE2","title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-01","conditions":["HER2-positive Breast Cancer"],"enrollment":0,"completionDate":"2028-06-30"},{"nctId":"NCT03740256","phase":"PHASE1","title":"Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2020-12-14","conditions":["Bladder Cancer","Head and Neck Squamous Cell Carcinoma","Cancer of the Salivary Gland","Lung Cancer","Breast Cancer","Gastric Cancer","Esophageal Cancer","Colorectal Cancer","Pancreatic Adenocarcinoma","Solid Tumor"],"enrollment":45,"completionDate":"2038-12-30"},{"nctId":"NCT06253871","phase":"PHASE1","title":"A Phase 1/1b Study of IAM1363 in HER2 Cancers","status":"RECRUITING","sponsor":"Iambic Therapeutics, Inc","startDate":"2024-03-25","conditions":["HER2 Mutation-Related Tumors","HER2","HER2-positive Breast Cancer","HER2 + Breast Cancer","Brain Metastases From Solid Tumors","Brain Metastases From HER2 and Breast Cancer","CNS Metastases","HER2-Positive Solid Tumors","NSCLC (Non-small Cell Lung Cancer)","HER2-positive Bladder Cancer","HER2-positive Colorectal Cancer","HER2 + Gastric Cancer","HER2-positive Gastroesophageal Cancer"],"enrollment":243,"completionDate":"2028-03"},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":["Endometrial Cancer"],"enrollment":480,"completionDate":"2029-11"},{"nctId":"NCT05161195","phase":"PHASE4","title":"Roll-over Study to Allow Continued Access to Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-07","conditions":["Metastatic Breast Cancer"],"enrollment":134,"completionDate":"2030-08-14"},{"nctId":"NCT04305496","phase":"PHASE3","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-04-16","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"enrollment":818,"completionDate":"2026-06-22"},{"nctId":"NCT04991480","phase":"PHASE1","title":"A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Artios Pharma Ltd","startDate":"2021-09-13","conditions":["Advanced Cancer","Metastatic Cancer","Breast Cancer"],"enrollment":93,"completionDate":"2025-12-24"},{"nctId":"NCT07366632","phase":"PHASE1","title":"A Study of Single Dose of BL0175 in Postmenopausal Women","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Best-Link Bioscience, LLC","startDate":"2026-01-26","conditions":["Postmenopausal Women"],"enrollment":27,"completionDate":"2026-12-21"},{"nctId":"NCT01494662","phase":"PHASE2","title":"HKI-272 for HER2-Positive Breast Cancer and Brain Metastases","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-02","conditions":["Breast Cancer"],"enrollment":140,"completionDate":"2024-04-19"},{"nctId":"NCT03289039","phase":"PHASE2","title":"Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-10-25","conditions":["Breast Cancer"],"enrollment":21,"completionDate":"2021-07-20"},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":["Estrogen-receptor-positive Breast Cancer","Metastatic Breast Cancer","Breast Cancer","Hormone Receptor Positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","HER2- Breast Cancer","ESR1 Gene Mutation","ER Wildtype","Breast Neoplasms"],"enrollment":297,"completionDate":"2030-10-01"},{"nctId":"NCT06084481","phase":"PHASE1","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-11-09","conditions":["Hepatocellular Carcinoma","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancers","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Cancer","Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","Head and Neck Squamous-Cell Carcinoma","Platinum Resistant High Grade Epithelial Ovarian Cancer"],"enrollment":302,"completionDate":"2026-07"},{"nctId":"NCT07221513","phase":"PHASE2","title":"Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension","status":"RECRUITING","sponsor":"Salubris Biotherapeutics Inc","startDate":"2025-12-15","conditions":["HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Group 2 Pulmonary Hypertension"],"enrollment":30,"completionDate":"2027-10"},{"nctId":"NCT06666439","phase":"","title":"Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer","status":"RECRUITING","sponsor":"Julia Foldi","startDate":"2024-12-12","conditions":["Metastatic Invasive Lobular Carcinoma (mILC)"],"enrollment":20,"completionDate":"2029-10-31"},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":["Breast Cancer"],"enrollment":250,"completionDate":"2026-04-30"},{"nctId":"NCT03685331","phase":"PHASE1","title":"HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-10-15","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer","Advanced Breast Cancer","BRCA2 Mutation","BRCA1 Mutation"],"enrollment":9,"completionDate":"2025-12-01"},{"nctId":"NCT06961331","phase":"","title":"Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-05-07","conditions":["Metastatic HER2+ Advanced Breast Cancer"],"enrollment":86,"completionDate":"2025-09-25"},{"nctId":"NCT04721977","phase":"PHASE2","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-04-08","conditions":["Breast Cancer"],"enrollment":66,"completionDate":"2026-06-30"},{"nctId":"NCT07330544","phase":"PHASE2","title":"A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-24","conditions":["Breast Cancer"],"enrollment":118,"completionDate":"2028-11-26"},{"nctId":"NCT05332002","phase":"PHASE2","title":"sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-07-13","conditions":["Gastro-Intestinal Cancer"],"enrollment":38,"completionDate":"2026-08-01"},{"nctId":"NCT05365178","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-07-01","conditions":["HR-positive, HER2-negative Breast Neoplasms"],"enrollment":432,"completionDate":"2026-06"},{"nctId":"NCT06408168","phase":"PHASE2","title":"Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-08-08","conditions":["Hormone Receptor-positive Human Epidermal Growth Factor 2-negative","Metastatic Invasive LObular Carcinoma"],"enrollment":6,"completionDate":"2025-12-08"},{"nctId":"NCT06715839","phase":"NA","title":"Target-specific immunoPET Imaging of Digestive System Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-12-04","conditions":["Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma"],"enrollment":400,"completionDate":"2027-09"},{"nctId":"NCT06452394","phase":"PHASE2","title":"NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2025-07-16","conditions":["Breast Cancer"],"enrollment":50,"completionDate":"2028-12-31"},{"nctId":"NCT05963984","phase":"PHASE2","title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-11-16","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer"],"enrollment":60,"completionDate":"2025-08-28"},{"nctId":"NCT07062965","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-05","conditions":["Breast Cancer"],"enrollment":400,"completionDate":"2030-11-04"},{"nctId":"NCT06210490","phase":"PHASE2","title":"A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-02-20","conditions":["Upper Urinary Tract Urothelial Carcinoma"],"enrollment":60,"completionDate":"2028-05-31"},{"nctId":"NCT06851442","phase":"PHASE1,PHASE2","title":"Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-05-16","conditions":["Breast Cancer"],"enrollment":8,"completionDate":"2025-11-20"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL2108314"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"NEPIDERMIN","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:36.361861+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}